论文部分内容阅读
目的 探讨齐拉西酮联合丙戊酸钠治疗双相障碍躁狂发作的临床疗效.方法 在2015年8月至2016年11月收治的双相障碍躁狂发作患者中,选择具有可比性的58例患者作为研究对象,随机分成观察组与对照组,观察组给予齐拉西酮联合丙戊酸钠治疗,对照组给予单一的丙戊酸钠治疗,分别对比两组患者临床疗效及治疗前、治疗后1、2、4周的YMRS评分.结果 观察组临床有效率为89.7％,明显优于对照组的65.5％,差异具有统计学意义(P＜0.05);两组治疗前YMRS评分差异不明显(P＞0.05),观察组在治疗后1、2 4周YMRS评分明显低于对照组,差异具有统计学意义(P＜0.05).结论 齐拉西酮联合丙戊酸钠治疗双相障碍躁狂发作临床疗效良好,缓解患者症状速度快,安全性高.“,”Objective To investigate the clinical efficacy of ziprasidone combined valproate in the treatment of bipolar manic episode.Methods From August 2015 to November 2016 bipolar manic patients,select comparable 58 patients as the research object,randomly divided into observation group and control group,the observation group was given ziprasidone with valproate therapy,the control group given single valproate treatment,respectively,compared two groups of patient's clinical curative effect and treatment before and after treatment the YMRS rating of 1,2,4.Results To observe the clinical effective rate was 89.7％,better than the control group 65.5％,the difference statistically significant (P ＜ 0.05);The two groups before treatment YMRS score difference is not obvious (P ＞ 0.05),the observation group 1,2,4 weeks after treatment YMRS score significantly lower than those the control group,the difference is statistically significant (P ＜ 0.05).Conclusion Ziprasidone combined valproate in the treatment of bipolar manic clinical curative effect is good,relieve symptoms speed,high safety.